Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.
Yang WangBing XiaLixia CaoJianfeng YangCui FengFangdun JiangChen LiLixia GuYifan YangJing TianXin ChengKeiji FuruuchiJames FulmerArielle VerdiKatherine RybinskiAllis SotoEarl AlboneToshimitsu UenakaLikun GongTingting LiuQiuping QinZiping WeiYuhong ZhouPublished in: Antibody therapeutics (2024)
The preclinical data support the test of BB-1701 in patients with various HER2-expressing cancers, including those resistant to other HER2-targeting ADCs. A phase I clinical trial of BB-1701 (NCT04257110) in patients is currently underway.
Keyphrases
- growth factor
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- recombinant human
- cancer therapy
- prognostic factors
- peritoneal dialysis
- phase ii
- randomized controlled trial
- electronic health record
- open label
- big data
- magnetic resonance imaging
- drug delivery
- magnetic resonance
- machine learning
- patient reported outcomes
- anti inflammatory
- double blind
- placebo controlled